Alzheimer’s Disease Cooperative Study, Biohaven Jointly Launch Clinical Trial for Trigriluzole

Alzheimer’s Disease Cooperative Study, Biohaven Jointly Launch Clinical Trial for Trigriluzole
Biohaven and the Alzheimer’s Disease Cooperative Study (ADCS) have jointly launched a Phase 2 clinical trial for the investigational drug trigriluzole, a glutamate modulating candidate that could potentially improve symptoms in patients with mild to moderate Alzheimer’s disease. Preclinical studies and post-mortem human Alzheimer’s studies suggest that abnormalities in the signaling of the neurotransmitter glutamate — the

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Molly Jones says:

    This is hard to follow: I thought Biohaven found a negative result for the trial “trigriluzole did not differentiate from placebo on primary endpoint or key secondary outcome” What is the difference here?

Leave a Comment

Your email address will not be published. Required fields are marked *